Clinical Scorecard: Geographic Atrophy Care in 2026
At a Glance
| Category | Detail |
|---|---|
| Condition | Geographic Atrophy (GA) |
| Key Mechanisms | Imaging features on OCT and FAF, complement inhibitors, emerging therapies targeting different pathways. |
| Target Population | Patients at risk for progression of geographic atrophy. |
| Care Setting | Optometry practices |
Key Highlights
- Early recognition of disease trajectory using OCT can identify warning signs years before significant vision loss.
- High-risk OCT features include hyper-reflective foci, large drusen volume, and outer retinal disruption.
- Current treatments can slow GA progression but do not restore vision.
- Emerging therapies include oral therapies, gene therapy, and AI-guided disease prediction.
- AI may help individualize treatment decisions based on patient progression.
Guideline-Based Recommendations
Diagnosis
- Utilize OCT and FAF imaging to identify high-risk features.
Management
- Educate patients on available therapies and make timely referrals.
Monitoring & Follow-up
- Document progression longitudinally and follow changes over time.
Risks
- Patients may experience significant vision loss if GA progresses unchecked.
Patient & Prescribing Data
Patients with early signs of geographic atrophy.
Current treatments include pegcetacoplan and avacincaptad pegol, which are complement inhibitors.
Clinical Best Practices
- Proactively counsel patients based on imaging biomarkers.
- Incorporate AI tools for predicting disease progression.
Related Resources & Content
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.